Clinical Trial Detail

NCT ID NCT03229200
Title Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Recruitment Enrolling by invitation
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Pharmacyclics Switzerland GmbH
Indications

lymphoma

leukemia

Advanced Solid Tumor

Therapies

Ibrutinib

Age Groups: adult senior

No variant requirements are available.